Birch DG, Anderson JL, Fish GE, Jost BF Pattern-reversal electroretinographic acuity in untreated eyes with subfoveal neovascular membranes. Invest Ophthalmol Vis Sci. 1992 Jun;33(7):2097-104.
Birch DG, Anderson JL, Fish GE, Jost BF Pattern-reversal electroretinographic follow-up of laser photocoagulation for subfoveal neovascular lesions in age-related macular degeneration. Am J Ophthalmol. 1993 Aug 15;116(2):148-55.
Blackhurst DW, Maguire MG Reproducibility of refraction and visual acuity measurement under a standard protocol. The Macular Photocoagulation Study Group. Retina. 1989;9(3):163-9.
Bressler NM, Bressler SB, Alexander J, Javornik N, Fine SL, Murphy RP Loculated fluid. A previously undescribed fluorescein angiographic finding in choroidal neovascularization associated with macular degeneration. Macular Photocoagulation Study Reading Center. Arch Ophthalmol. 1991 Feb;109(2):211-5.
Bressler SB, Maguire MG, Bressler NM, Fine SL Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol. 1990 Oct;108(10):1442-7.
Hawkins BS, Prior MJ, Fisher MR, Blackhurst DW Relationship between rate of patient enrollment and quality of clinical center performance in two multicenter trials in ophthalmology. Control Clin Trials. 1990 Oct;11(5):374-94.
Hillis A, Maguire M, Hawkins BS, Newhouse MM The Markov process as a general method for nonparametric analysis of right-censored medical data. J Chronic Dis. 1986;39(8):595-604.
Occult choroidal neovascularization Influence on visual outcome in patients with age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1996 Apr;114(4):400-12. Erratum in: Arch Ophthalmol 1996 Aug;114(8):1023.
Orr PR, Blackhurst DW, Hawkins BS Patient and clinic factors predictive of missed visits and inactive status in a multicenter clinical trial. The Macular Photocoagulation Study Group. Control Clin Trials. 1992 Feb;13(1):40-9.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
